Statement Of Cash Flows [Abstract]

BerGenBio - Filing #5877180

Concept 2024-01-01 to
2024-12-31
As at
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operating activities
153,242,000 NOK
225,101,000 NOK
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities
167,000 NOK
0 NOK
Interest received, classified as investing activities
3,521,000 NOK
3,055,000 NOK
Cash flows from (used in) investing activities
3,688,000 NOK
3,055,000 NOK
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
138,874,000 NOK
262,048,000 NOK
Payments of lease liabilities, classified as financing activities
438,000 NOK
193,000 NOK
Cash flows from (used in) financing activities
129,609,000 NOK
224,884,000 NOK
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
19,945,000 NOK
2,838,000 NOK
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
3,678,000 NOK
2,780,000 NOK
Cash and cash equivalents
140,155,000 NOK
156,421,000 NOK
150,803,000 NOK

Talk to a Data Expert

Have a question? We'll get back to you promptly.